Last reviewed · How we verify
NCT03876574
Hepatic Artery Infusion Pump for NPC Liver Metastases
Phase 1 trial testing DSA-guided implantation of hepatic artery infusion pump in Nasopharyngeal Carcinoma in 16 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 1 January 2011 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
Drugs / interventions tested
- DSA-guided implantation of hepatic artery infusion pump
- Gemcitabine (gemcitabine) — full drug profile →
- Floxuridine (FLOXURIDINE) — full drug profile →
- dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Liver — all drugs for Liver →
Sponsor
Xiangya Hospital of Central South University
Who can join
Eligibility, any sex, with Nasopharyngeal Carcinoma or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver. Hepatic-direction drug administration improves the control power for intra-hapatic lesions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03876574
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Carcinoma
Currently open trials in the same condition.
- NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
- NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
- NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
- NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03876574 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 15 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03876574.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing